DE8625574U1 - Hypodermic needle - Google Patents

Description

fr »f ■ t · ■ · ■ ■ Il I 1

• C · ■ · ■■■■ ι I) ϊ 1

ll »l

Schering Akliengesellschaft ·· · _β · · ·? ι »» »

Commercial legal protection * * * ········ ■ · · * " ^{) J}

SCHERING

Injection needle II

i "Postal address: Schering Alcjingesellschalt, Postlach 65 0311," -1000 Berlin 65 ' for visitors: Borlin-Wedding, Müllerslraüe 170Ί78 - Tololon: (OdO) 468-0

■ 'i telegrams; Scheringchemie Berlin · Telex; 182 03-0 sch d

: i Z Board of Directors: Herberl Asmig, Christian Brunn, Heinz Hannse, Horsl Kramp, Klaus POhIe ₁ Horst Wilzel ■ Chairman of the Aulsichtsrals: Klaus Subjetzkl ■ Headquarters dBf Society:

1 I Berlin and Bergkamen ■ Commercial register: AG Chsf IblnnbWg 93 WhB zSä untlVd Kameji S) RB 0061 Berliner Commerzbank AG, Berlin, KonlO'Nf, 108700BOÖ, BankleiUahl

¹¹¹ J 100 40000 Berliner Handels ·· and Frankfurter BinV, Efe! Lti> Korilo-fV. %) Cf4 ^ 5Z4, Bankfeillahl 100 202 00 Deutsche Bank Berlin AG, Korito 'No. 2415008, bank loan number

i «5 1ÖÖ 7ÖOÖÖ-Postgifoamt Berlin West, KNit ^ lVtilpDlO ' ·

• German · · · ■ * · t »* t ·

• »• 4 I4H IHI ^ It ·· · · ··

St.

The invention relates to the objects characterized in the claims.

For the treatment of certain diseases such as disease For Parkinson's disease, a continuous or periodic supply of the medicinal agent solution is desirable, since this is the only way to maintain a constant blood level of remedies is guaranteed. To give the patient freedom of movement received in order to avoid inpatient treatment. and to rule out incorrect intake, one usually uses an electric metering pump that is worn on the body and that delivers the remedy via a hose line through an injection cannula fixed in the aiuitanenv ^ ftuskel-tissue. This naturally occurs at the point of entry in the body tissue

higher concentrations of remedies, because from there the remedy - due to the concentration gradient to the rest of the tissue - is distributed in the body. The higher concentration of remedies occurring at the injection site can - depending on the chemical nature of the remedy and its concentration - lead to local irritation and inflammation-like conditions which, in extreme cases, make it necessary to terminate the therapy. One solution to this problem is to enlarge the injection area, as a result of which the amount of therapeutic agent per unit area is reduced while the injection speed and concentration of the therapeutic agent solution remain the same. The injection syringes provided by the prior art either do not offer this option at all (Belgian patent No. 860.017, US patent No. 12665 ² O, UK patent application GB 2'057269 A) or they have other serious disadvantages US Patent 4159720 describes a device that brings the medicinal solution from a storage container attached to the skin through a wick made of silk or irecSziniscran suture material in the tissue into cfei iijcper- This method has the disadvantage that the dosage is predetermined and by the wick surface is constant, so that no dosage adapted to the daily profile is possible. In addition, the tissue compatibility of the wick material must be ensured in the special case.

In the German Offenlegungsschrift DE 3035009, a syringe head described, which is provided with 5 nozzles for receiving injection needles. However, this is used as part of a hypodermic syringe Wheal formation provided. Due to the spatial extent and the structural details of the syringe head and the nozzle for mounting

If the hypodermic needle were to be used, this device is not suitable after fixation at the desired injection site on the body for a long time to be asked.

Proceeding from this prior art, the object of the invention is to be found based on a continuous injection that is used to treat various diseases it is necessary to increase the concentration by enlarging the injection area to reduce the medicinal product solution at the point of entry with a constant inflow speed, in order to reduce the risk of high medicinal products' concentration at the point of entry caused tissue irritation and inflammation. For this purpose, the injection needle should .. · be easy to fix at the injection site and lie flat on the body without taking up too much space.

According to the invention, this is achieved in that the injection needle is made of physiologically compatible material with a total length of 50 to 60 mm, a clear width of 0.15 to 0.25 mm - and an outer diameter of 0.4 to 0.5 mm, is provided with a closed cannula point and has 6 to 8 lateral outlet openings with a diameter of 0.15 to 0.2 mm, the opening adjacent to the cannula point being 0.4 to 0.6 mm away from it and the other openings in one A distance of 4 to 6 mm from one another in the longitudinal axis, but are arranged spirally offset by 50 ° to 70 °, so that the area provided with outlet openings comprises 23.5 to 33.5 mm. The straight part of the injection syringe without bores serves as a connection to the supply hose leading to the dosing device. The injection ^needle has a clear diameter of 0.15 to 0.25 mm and an outer diameter of 0.4 to 0.5 mm.

An embodiment is explained in more detail with reference to the drawings, and although shows:

Fig. 1 is a sectional side view of the injection needle and

Fig. 2 is a side view of the injection needle with attached Supply hose and Luer-Look connection.

Through the distribution of the medicinal solution supplied with the dosing device the concentration of the therapeutic agent per tissue area is reduced to several outlet openings.

Il · I

Il · I.. .

I J ι ι ι it

I - 4 -ι ι

> · Ι I III

I III

> I II M

The handling of the invention. Injection needle is as follows:

The whole system (metering device, supply hose and inventive injection syringe) is filled with the hay solution without bubbles and as flat as possible at the desired point in the body "tissue" pierced, "up to the syringe part with holes is located in the body tissue.

The injection needle is now covered by a physiologically compatible plaster o.a. fixed to the body and the dosing device put into operation.

Claims (4)

r a ff · ■ CLAIMS FOR PROTECTION 1. Injection needle for continuous or periodic subcutaneous or intramuscular introduction of an aqueous or oily medicinal product physiologically compatible material with a total length of 50 to 60 πτπ, a clear width of 0.15 to 0.25 mm and an outside diameter from 0.4 to 0.5 mm, is provided with a closed cannula point and 6 to 8 lateral outlet openings with a diameter of 0.15 to 0.2 mm, the first opening 0.4 to 0.6 mm from the cannula bevel and the other openings at a distance from 4 to 6 mm from one another in the longitudinal axis, however, are arranged spirally offset by 50 ° to 70 °. 2. Injection needle according to claim 1, characterized in that it consists of . Nirojta steel is made. 3. Injection needle according to claim 1 and 2, characterized in that the total length is 50 mm, the clear width is 0.2 mm and the outer diameter is 0.45 mm. 4. Injection. Needle according to Claim 3, characterized in that it with 6 lateral exit openings with a diameter of 0.2 mm is provided, the first opening 0.5 mm from the cannula bevel and the other 5 openings at a distance of 5 mm from each other but are arranged helically offset by 60 ° in the longitudinal axis. l im «« · * * ίt * I «ilt · · · * ■ * ··